{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:34:47Z","timestamp":1788305687496,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20CIII\/00020"],"award-info":[{"award-number":["PI20CIII\/00020"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008545","name":"Asociaci\u00f3n Pablo Ugarte","doi-asserted-by":"publisher","award":["TRVP 205\/18"],"award-info":[{"award-number":["TRVP 205\/18"]}],"id":[{"id":"10.13039\/501100008545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asociaci\u00f3n Todos somos Iv\u00e1n and Asociaci\u00f3n Candela Riera","award":["TVP 333\/19"],"award-info":[{"award-number":["TVP 333\/19"]}]},{"name":"Fundaci\u00f3n FEDER","award":["SIVI 124\/24"],"award-info":[{"award-number":["SIVI 124\/24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14945-6","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:00:33Z","timestamp":1754636433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Suicide gene therapy targeting ewing sarcoma via an ewing-specific GGAA promoter"],"prefix":"10.1038","volume":"15","author":[{"given":"Saint T.","family":"Cervera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Iranzo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel M. Melero-Fern\u00e1ndez","family":"de Mera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"14945_CR1","doi-asserted-by":"publisher","unstructured":"Anderton, J. et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 protocol. Trials 21 (96). https:\/\/doi.org\/10.1186\/s13063-019-4026-8 (2020).","DOI":"10.1186\/s13063-019-4026-8"},{"key":"14945_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","volume":"400","author":"B Brennan","year":"2022","unstructured":"Brennan, B. et al. Comparison of two chemotherapy regimens in patients with newly diagnosed ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet 400, 1513\u20131521. https:\/\/doi.org\/10.1016\/S0140-6736(22)01790-1 (2022).","journal-title":"Lancet"},{"key":"14945_CR3","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar, N. et al. Ewing sarcoma: current management and future approaches through collaboration. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 33, 3036\u20133046. https:\/\/doi.org\/10.1200\/JCO.2014.59.5256 (2015).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"14945_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/cam4.3712","volume":"10","author":"A Felix","year":"2021","unstructured":"Felix, A. et al. Systematic review of phase-I\/II trials enrolling refractory and recurrent ewing sarcoma: actual knowledge and future directions to optimize the research. Cancer Med. 10, 1589\u20131604. https:\/\/doi.org\/10.1002\/cam4.3712 (2021).","journal-title":"Cancer Med."},{"key":"14945_CR5","doi-asserted-by":"publisher","first-page":"8613","DOI":"10.18632\/oncotarget.6937","volume":"7","author":"H Kovar","year":"2016","unstructured":"Kovar, H. et al. The second European interdisciplinary ewing sarcoma research summit\u2013A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget 7, 8613\u20138624. https:\/\/doi.org\/10.18632\/oncotarget.6937 (2016).","journal-title":"Oncotarget"},{"key":"14945_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fonc.2012.00054","volume":"2","author":"H Kovar","year":"2012","unstructured":"Kovar, H. et al. The first European interdisciplinary ewing sarcoma research summit. Front. Oncol. 2, 54. https:\/\/doi.org\/10.3389\/fonc.2012.00054 (2012).","journal-title":"Front. Oncol."},{"key":"14945_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1055\/s-0035-1545263","volume":"227","author":"T Bolling","year":"2015","unstructured":"Bolling, T. et al. Development of curative therapies for ewing sarcomas by interdisciplinary cooperative groups in Europe. Klin. Padiatr. 227, 108\u2013115. https:\/\/doi.org\/10.1055\/s-0035-1545263 (2015).","journal-title":"Klin. Padiatr."},{"key":"14945_CR8","doi-asserted-by":"publisher","unstructured":"Liu, J., Pandya, P. & Afshar, S. Therapeutic advances in oncology. Int. J. Mol. Sci. 22. https:\/\/doi.org\/10.3390\/ijms22042008 (2021).","DOI":"10.3390\/ijms22042008"},{"key":"14945_CR9","doi-asserted-by":"publisher","unstructured":"Zollner, S. K. et al. Ewing Sarcoma-Diagnosis, treatment, clinical challenges and future perspectives. J. Clin. Med. 10. https:\/\/doi.org\/10.3390\/jcm10081685 (2021).","DOI":"10.3390\/jcm10081685"},{"key":"14945_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"O Delattre","year":"1992","unstructured":"Delattre, O. et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162\u2013165. https:\/\/doi.org\/10.1038\/359162a0 (1992).","journal-title":"Nature"},{"key":"14945_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-biochem-060614-034325","volume":"84","author":"JC Schwartz","year":"2015","unstructured":"Schwartz, J. C., Cech, T. R. & Parker, R. R. Biochemical properties and biological functions of FET proteins. Annu. Rev. Biochem. 84, 355\u2013379. https:\/\/doi.org\/10.1146\/annurev-biochem-060614-034325 (2015).","journal-title":"Annu. Rev. Biochem."},{"key":"14945_CR12","first-page":"257","volume":"59","author":"R Hromas","year":"1994","unstructured":"Hromas, R. & Klemsz, M. The ETS oncogene family in development, proliferation and neoplasia. Int. J. Hematol. 59, 257\u2013265 (1994).","journal-title":"Int. J. Hematol."},{"key":"14945_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Grunewald","year":"2018","unstructured":"Grunewald, T. G. P. et al. Ewing sarcoma. Nat. Rev. Dis. Primers. 4, 5. https:\/\/doi.org\/10.1038\/s41572-018-0003-x (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"14945_CR14","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1038\/onc.2008.203","volume":"27","author":"E Garcia-Aragoncillo","year":"2008","unstructured":"Garcia-Aragoncillo, E. et al. DAX1, a direct target of EWS\/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in ewing\u2019s tumor cells. Oncogene 27, 6034\u20136043. https:\/\/doi.org\/10.1038\/onc.2008.203 (2008).","journal-title":"Oncogene"},{"key":"14945_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41417-025-00887-8","volume":"32","author":"ST Cervera","year":"2025","unstructured":"Cervera, S. T. et al. Targeted inactivation of EWSR1::FLI1 gene in ewing sarcoma via CRISPR\/Cas9 driven by an ewing-specific GGAA promoter. Cancer Gene Ther. 32, 437\u2013449. https:\/\/doi.org\/10.1038\/s41417-025-00887-8 (2025).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR16","doi-asserted-by":"publisher","unstructured":"Cervera, S. T. et al. Therapeutic potential of EWSR1-FLI1 inactivation by CRISPR\/Cas9 in ewing sarcoma. Cancers 13. https:\/\/doi.org\/10.3390\/cancers13153783 (2021).","DOI":"10.3390\/cancers13153783"},{"key":"14945_CR17","first-page":"5276","volume":"46","author":"FL Moolten","year":"1986","unstructured":"Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276\u20135281 (1986).","journal-title":"Cancer Res."},{"key":"14945_CR18","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.ymthe.2021.04.006","volume":"29","author":"S Sheikh","year":"2021","unstructured":"Sheikh, S., Ernst, D. & Keating, A. Prodrugs and prodrug-activated systems in gene therapy. Mol. Therapy: J. Am. Soc. Gene Therapy. 29, 1716\u20131728. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.006 (2021).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"14945_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/jnci\/82.4.297","volume":"82","author":"FL Moolten","year":"1990","unstructured":"Moolten, F. L. & Wells, J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl Cancer Inst. 82, 297\u2013300. https:\/\/doi.org\/10.1093\/jnci\/82.4.297 (1990).","journal-title":"J. Natl Cancer Inst."},{"key":"14945_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/hum.1990.1.2-125","volume":"1","author":"FL Moolten","year":"1990","unstructured":"Moolten, F. L., Wells, J. M., Heyman, R. A. & Evans, R. M. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1, 125\u2013134. https:\/\/doi.org\/10.1089\/hum.1990.1.2-125 (1990).","journal-title":"Hum. Gene Ther."},{"key":"14945_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1089\/10430340050083298","volume":"11","author":"J Qiao","year":"2000","unstructured":"Qiao, J., Black, M. E. & Caruso, M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum. Gene Ther. 11, 1569\u20131576. https:\/\/doi.org\/10.1089\/10430340050083298 (2000).","journal-title":"Hum. Gene Ther."},{"key":"14945_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.cgt.7700113","volume":"7","author":"YG Kim","year":"2000","unstructured":"Kim, Y. G., Bi, W., Feliciano, E. S., Drake, R. R. & Stambrook, P. J. Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene. Cancer Gene Ther. 7, 240\u2013246. https:\/\/doi.org\/10.1038\/sj.cgt.7700113 (2000).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR23","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.3390\/molecules14114517","volume":"14","author":"GU Dachs","year":"2009","unstructured":"Dachs, G. U., Hunt, M. A., Syddall, S., Singleton, D. C. & Patterson, A. V. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 14, 4517\u20134545. https:\/\/doi.org\/10.3390\/molecules14114517 (2009).","journal-title":"Molecules"},{"key":"14945_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1566523023347733","volume":"2","author":"IJ van Dillen","year":"2002","unstructured":"van Dillen, I. J., Mulder, N. H., Vaalburg, W., de Vries, E. F. & Hospers, G. A. Influence of the bystander effect on HSV-tk\/GCV gene therapy. A review. Curr. Gene Ther. 2, 307\u2013322. https:\/\/doi.org\/10.2174\/1566523023347733 (2002).","journal-title":"Curr. Gene Ther."},{"key":"14945_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/sj.cgt.7700389","volume":"8","author":"T Maeda","year":"2001","unstructured":"Maeda, T. et al. A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. Cancer Gene Ther. 8, 890\u2013896. https:\/\/doi.org\/10.1038\/sj.cgt.7700389 (2001).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR26","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/15207","volume":"5","author":"RA Dewey","year":"1999","unstructured":"Dewey, R. A. et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med. 5, 1256\u20131263. https:\/\/doi.org\/10.1038\/15207 (1999).","journal-title":"Nat. Med."},{"key":"14945_CR27","doi-asserted-by":"publisher","first-page":"vdaa013","DOI":"10.1093\/noajnl\/vdaa013","volume":"2","author":"JA Hossain","year":"2020","unstructured":"Hossain, J. A., Marchini, A., Fehse, B., Bjerkvig, R. & Miletic, H. Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. Neurooncol Adv. 2, vdaa013. https:\/\/doi.org\/10.1093\/noajnl\/vdaa013 (2020).","journal-title":"Neurooncol Adv."},{"key":"14945_CR28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3892\/ijo.2014.2557","volume":"45","author":"K Higashi","year":"2014","unstructured":"Higashi, K. et al. A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model. Int. J. Oncol. 45, 1412\u20131420. https:\/\/doi.org\/10.3892\/ijo.2014.2557 (2014).","journal-title":"Int. J. Oncol."},{"key":"14945_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/10430340252898966","volume":"13","author":"AJ Pantuck","year":"2002","unstructured":"Pantuck, A. J. et al. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum. Gene Ther. 13, 777\u2013789. https:\/\/doi.org\/10.1089\/10430340252898966 (2002).","journal-title":"Hum. Gene Ther."},{"key":"14945_CR30","doi-asserted-by":"publisher","first-page":"15015","DOI":"10.1038\/mto.2015.15","volume":"2","author":"TP Cripe","year":"2015","unstructured":"Cripe, T. P. et al. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Mol. Ther. Oncolytics. 2, 15015. https:\/\/doi.org\/10.1038\/mto.2015.15 (2015).","journal-title":"Mol. Ther. Oncolytics"},{"key":"14945_CR31","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/mto.2015.16","volume":"2","author":"GK Friedman","year":"2015","unstructured":"Friedman, G. K. et al. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol. Ther. Oncolytics. 2, 15016. https:\/\/doi.org\/10.1038\/mto.2015.16 (2015).","journal-title":"Mol. Ther. Oncolytics"},{"key":"14945_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/neuonc\/noy202","volume":"21","author":"MW Kieran","year":"2019","unstructured":"Kieran, M. W. et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 21, 537\u2013546. https:\/\/doi.org\/10.1093\/neuonc\/noy202 (2019).","journal-title":"Neuro Oncol."},{"key":"14945_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2017.07.006","volume":"189","author":"PR Lowenstein","year":"2018","unstructured":"Lowenstein, P. R. & Castro, M. G. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clin. Immunol. 189, 43\u201351. https:\/\/doi.org\/10.1016\/j.clim.2017.07.006 (2018).","journal-title":"Clin. Immunol."},{"key":"14945_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/cgt.2013.56","volume":"20","author":"A Rojas-Mart\u00ednez","year":"2013","unstructured":"Rojas-Mart\u00ednez, A. et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 20, 642\u2013649. https:\/\/doi.org\/10.1038\/cgt.2013.56 (2013).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ymthe.2020.11.001","volume":"29","author":"JD Predina","year":"2021","unstructured":"Predina, J. D. et al. Neoadjuvant Gene-Mediated cytotoxic immunotherapy for Non-Small-Cell lung cancer: safety and Immunologic activity. Mol. Therapy: J. Am. Soc. Gene Therapy. 29, 658\u2013670. https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.001 (2021).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"14945_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","volume":"8","author":"S Thoidingjam","year":"2023","unstructured":"Thoidingjam, S. et al. Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford health. Transl Med. Commun. 8, 11. https:\/\/doi.org\/10.1186\/s41231-023-00144-w (2023).","journal-title":"Transl Med. Commun."},{"key":"14945_CR37","doi-asserted-by":"publisher","first-page":"1183295","DOI":"10.3389\/fped.2023.1183295","volume":"11","author":"L Moreno","year":"2023","unstructured":"Moreno, L. et al. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene Laherparepvec in pediatric patients with advanced solid tumors. Front. Pead. 11, 1183295. https:\/\/doi.org\/10.3389\/fped.2023.1183295 (2023).","journal-title":"Front. Pead."},{"key":"14945_CR38","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.ymthe.2019.08.020","volume":"27","author":"KA Streby","year":"2019","unstructured":"Streby, K. A. et al. First-in-Human intravenous seprehvir in young cancer patients: A phase 1 clinical trial. Mol. Therapy: J. Am. Soc. Gene Therapy. 27, 1930\u20131938. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.020 (2019).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"14945_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/cgt.2010.40","volume":"17","author":"B Sangro","year":"2010","unstructured":"Sangro, B. et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 17, 837\u2013843. https:\/\/doi.org\/10.1038\/cgt.2010.40 (2010).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/cgt.2009.60","volume":"17","author":"A Ardiani","year":"2010","unstructured":"Ardiani, A., Sanchez-Bonilla, M. & Black, M. E. Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther. 17, 86\u201396. https:\/\/doi.org\/10.1038\/cgt.2009.60 (2010).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR41","doi-asserted-by":"publisher","unstructured":"Locatelli, M. et al. Optimization of thymidine kinase-based safety switch for neural cell therapy. Cells 11. https:\/\/doi.org\/10.3390\/cells11030502 (2022).","DOI":"10.3390\/cells11030502"},{"key":"14945_CR42","doi-asserted-by":"publisher","unstructured":"Macedo, N., Miller, D. M., Haq, R. & Kaufman, H. L. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer 8. https:\/\/doi.org\/10.1136\/jitc-2020-001486 (2020).","DOI":"10.1136\/jitc-2020-001486"},{"key":"14945_CR43","doi-asserted-by":"publisher","first-page":"200822","DOI":"10.1016\/j.omton.2024.200822","volume":"32","author":"SI Robinson","year":"2024","unstructured":"Robinson, S. I., Rochell, R. E., Penza, V. & Naik, S. Translation of oncolytic viruses in sarcoma. Mol. Ther. Oncol. 32, 200822. https:\/\/doi.org\/10.1016\/j.omton.2024.200822 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"14945_CR44","doi-asserted-by":"publisher","unstructured":"Rice, A. M. et al. Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J. Pediatr. Hematology\/oncol. 24, 527\u2013533. https:\/\/doi.org\/10.1097\/00043426-200210000-00006 (2002).","DOI":"10.1097\/00043426-200210000-00006"},{"key":"14945_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/s0165-0173(99)00099-5","volume":"32","author":"AF Andrade-Rozental","year":"2000","unstructured":"Andrade-Rozental, A. F. et al. Gap junctions: the kiss of death and the kiss of life. Brain Res. Brain Res. Rev. 32, 308\u2013315. https:\/\/doi.org\/10.1016\/s0165-0173(99)00099-5 (2000).","journal-title":"Brain Res. Brain Res. Rev."},{"key":"14945_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.14670\/HH-18.495","volume":"18","author":"TW Nicholas","year":"2003","unstructured":"Nicholas, T. W., Read, S. B., Burrows, F. J. & Kruse, C. A. Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol. Histopathol. 18, 495\u2013507. https:\/\/doi.org\/10.14670\/HH-18.495 (2003).","journal-title":"Histol. Histopathol"},{"key":"14945_CR47","first-page":"6228","volume":"54","author":"RG Vile","year":"1994","unstructured":"Vile, R. G., Nelson, J. A., Castleden, S., Chong, H. & Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228\u20136234 (1994).","journal-title":"Cancer Res."},{"key":"14945_CR48","first-page":"83","volume":"3","author":"S Gagandeep","year":"1996","unstructured":"Gagandeep, S. et al. Prodrug-activated gene therapy: involvement of an immunological component in the bystander effect. Cancer Gene Ther. 3, 83\u201388 (1996).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/cgt.2011.56","volume":"18","author":"JD Predina","year":"2011","unstructured":"Predina, J. D. et al. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther. 18, 871\u2013883. https:\/\/doi.org\/10.1038\/cgt.2011.56 (2011).","journal-title":"Cancer Gene Ther."},{"key":"14945_CR50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/neuonc\/nox139","volume":"20","author":"MC Speranza","year":"2018","unstructured":"Speranza, M. C. et al. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint Blockade in glioblastoma. Neuro Oncol. 20, 225\u2013235. https:\/\/doi.org\/10.1093\/neuonc\/nox139 (2018).","journal-title":"Neuro Oncol."},{"key":"14945_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<374::AID-IJC13>3.0.CO;2-#","volume":"83","author":"S Kuriyama","year":"1999","unstructured":"Kuriyama, S. et al. Cancer gene therapy with HSV-tk\/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int. J. Cancer. 83, 374\u2013380 (1999).","journal-title":"Int. J. Cancer"},{"key":"14945_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","volume":"64","author":"LK Aguilar","year":"2015","unstructured":"Aguilar, L. K. et al. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol. Immunotherapy: CII. 64, 727\u2013736. https:\/\/doi.org\/10.1007\/s00262-015-1679-3 (2015).","journal-title":"Cancer Immunol. Immunotherapy: CII"},{"key":"14945_CR53","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","volume":"29","author":"EA Chiocca","year":"2011","unstructured":"Chiocca, E. A. et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 29, 3611\u20133619. https:\/\/doi.org\/10.1200\/JCO.2011.35.5222 (2011).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"14945_CR54","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1089\/104303401753204535","volume":"12","author":"BJ Miles","year":"2001","unstructured":"Miles, B. J. et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12, 1955\u20131967. https:\/\/doi.org\/10.1089\/104303401753204535 (2001).","journal-title":"Hum. Gene Ther."},{"key":"14945_CR55","doi-asserted-by":"publisher","unstructured":"Evdokimova, V., Gassmann, H., Radvanyi, L. & Burdach, S. E. G. Current state of immunotherapy and mechanisms of immune evasion in ewing sarcoma and osteosarcoma. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15010272 (2022).","DOI":"10.3390\/cancers15010272"},{"key":"14945_CR56","doi-asserted-by":"publisher","first-page":"110047","DOI":"10.1016\/j.celrep.2021.110047","volume":"37","author":"AS Brohl","year":"2021","unstructured":"Brohl, A. S. et al. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell. Rep. 37, 110047. https:\/\/doi.org\/10.1016\/j.celrep.2021.110047 (2021).","journal-title":"Cell. Rep."},{"key":"14945_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2022.03.012","volume":"170","author":"MD Thakur","year":"2022","unstructured":"Thakur, M. D. et al. Immune contexture of paediatric cancers. Eur. J. Cancer. 170, 179\u2013193. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.012 (2022).","journal-title":"Eur. J. Cancer"},{"key":"14945_CR58","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-22-1471","volume":"28","author":"AR Cillo","year":"2022","unstructured":"Cillo, A. R. et al. Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks. Clin. Cancer Research: Official J. Am. Association Cancer Res. 28, 4968\u20134982. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1471 (2022).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"key":"14945_CR59","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2767-9764.CRC-23-0027","volume":"3","author":"LL Visser","year":"2023","unstructured":"Visser, L. L. et al. Ewing sarcoma Single-cell transcriptome analysis reveals functionally impaired Antigen-presenting cells. Cancer Res. Commun. 3, 2158\u20132169. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0027 (2023).","journal-title":"Cancer Res. Commun."},{"key":"14945_CR60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin, J. et al. Humanized mouse models for immuno-oncology research. Nat. Rev. Clin. Oncol. 20, 192\u2013206. https:\/\/doi.org\/10.1038\/s41571-022-00721-2 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"14945_CR61","doi-asserted-by":"publisher","unstructured":"Luo, W. et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in ewing sarcoma. Front. Immunol. 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1277987 (2023).","DOI":"10.3389\/fimmu.2023.1277987"},{"key":"14945_CR62","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.ijrobp.2003.09.083","volume":"58","author":"BS Teh","year":"2004","unstructured":"Teh, B. S. et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int. J. Radiat. Oncol. Biol. Phys. 58, 1520\u20131529. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.09.083 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"14945_CR63","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1006\/gyno.2001.6442","volume":"83","author":"A Hasenburg","year":"2001","unstructured":"Hasenburg, A. et al. Adenovirus-mediated thymidine kinase gene therapy in combination with Topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol. 83, 549\u2013554. https:\/\/doi.org\/10.1006\/gyno.2001.6442 (2001).","journal-title":"Gynecol. Oncol."},{"key":"14945_CR64","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/neuonc\/now002","volume":"18","author":"LA Wheeler","year":"2016","unstructured":"Wheeler, L. A. et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol. 18, 1137\u20131145. https:\/\/doi.org\/10.1093\/neuonc\/now002 (2016).","journal-title":"Neuro Oncol."},{"key":"14945_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/mthe.2000.0030","volume":"1","author":"TW Trask","year":"2000","unstructured":"Trask, T. W. et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Therapy: J. Am. Soc. Gene Therapy. 1, 195\u2013203. https:\/\/doi.org\/10.1006\/mthe.2000.0030 (2000).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"14945_CR66","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","volume":"26","author":"C Aggarwal","year":"2018","unstructured":"Aggarwal, C. et al. Phase I study of intrapleural Gene-Mediated cytotoxic immunotherapy in patients with malignant pleural effusion. Mol. Therapy: J. Am. Soc. Gene Therapy. 26, 1198\u20131205. https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.015 (2018).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"14945_CR67","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/10430349950018229","volume":"10","author":"JR Herman","year":"1999","unstructured":"Herman, J. R. et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 10, 1239\u20131249. https:\/\/doi.org\/10.1089\/10430349950018229 (1999).","journal-title":"Hum. Gene Ther."},{"key":"14945_CR68","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12943-022-01641-6","volume":"21","author":"TLB Holting","year":"2022","unstructured":"Holting, T. L. B. et al. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma. Mol. Cancer. 21, 199. https:\/\/doi.org\/10.1186\/s12943-022-01641-6 (2022).","journal-title":"Mol. Cancer"},{"key":"14945_CR69","first-page":"3022","volume":"61","author":"ME Black","year":"2001","unstructured":"Black, M. E., Kokoris, M. S. & Sabo, P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61, 3022\u20133026 (2001).","journal-title":"Cancer Res."},{"key":"14945_CR70","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1110\/ps.2460102","volume":"11","author":"MS Kokoris","year":"2002","unstructured":"Kokoris, M. S. & Black, M. E. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci. 11, 2267\u20132272. https:\/\/doi.org\/10.1110\/ps.2460102 (2002).","journal-title":"Protein Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14945-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14945-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14945-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:33:23Z","timestamp":1757352803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14945-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14945"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14945-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Experiments with animals were performed according to animal welfare guidelines and were approved by the Animal Experimentation Ethics Committee of the Instituto de Salud Carlos III (CBA 25_2020 and CBA 24_2022) and the Agriculture Department of the Madrid Region (PROEX 253.8\/20 and PROEX 302.3\/22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"29020"}}